Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors | Zendy

Dafna D. Gladman | Zendy; William F. C. Rigby | Zendy; Valdeŕilio Feijó Azevedo | Zendy; Frank Behrens | Zendy; Ricardo Blanco | Zendy; Andrzej Kaszuba | Zendy; Elizabeth M. Kudlacz | Zendy; Cunshan Wang | Zendy; Sujatha Me | Zendy; Thijs Hendrikx | Zendy; Keith S. Kanik | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

Author(s) -

Dafna D. Gladman,

William F. C. Rigby,

Valdeŕilio Feijó Azevedo,

Frank Behrens,

Ricardo Blanco,

Andrzej Kaszuba,

Elizabeth M. Kudlacz,

Cunshan Wang,

Sujatha Me,

Thijs Hendrikx,

Keith S. Kanik

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1615977

Subject(s) - tofacitinib , psoriatic arthritis , medicine , psoriasis , arthritis , tumor necrosis factor alpha , dermatology , rheumatoid arthritis

Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who had previously had an inadequate response to tumor necrosis factor (TNF) inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research